文献速递白血病

浆细胞样树突状细胞扩增定义RUNX1突变急性髓系白血病的一个独特亚群

Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia.
PubMed 文献 · Blood · 2021-01-01

研究描述了伴浆细胞样树突状细胞扩增的急性髓系白血病(pDC-AML),约占AML的5%,常伴跨系抗原表达且预后不良。RUNX1突变是该亚群最常见体细胞改变(>70%),pDC与白血病原始细胞克隆相关并源于后者。CD123靶向药tagraxofusp在患者来源异种移植模型中减少白血病负荷并清除pDC。

要点

  • pDC-AML约占AML的5%,常伴跨系抗原表达且预后不良。
  • RUNX1突变在pDC-AML中频率>70%,显著高于无pDC扩增的AML和BPDCN。
  • tagraxofusp在PDX模型中减少白血病负荷并清除pDC,提示CD123靶向治疗潜力。

核心结论

  • pDC-AML以高频RUNX1突变和pDC转录程序上调为特征,CD123靶向是潜在治疗方向。

研究设计与样本

  • 研究对伴pDC扩增的AML患者进行特征分析,并在患者来源异种移植模型中进行验证。

主要发现

  • pDC-AML约占AML病例的5%,常具跨系抗原表达且危险分层 adverse、结局差。
  • RUNX1突变是pDC-AML最常见体细胞改变(>70%),比无pDC扩增的AML和BPDCN更常见。
  • pDC与白血病原始细胞克隆相关并起源于后者,RUNX1突变AML的原始细胞上调pDC转录程序。
  • tagraxofusp在患者来源异种移植模型中减少白血病负荷并清除pDC。

关键数值与推荐

  • pDC-AML约占AML的5%。
  • RUNX1突变在pDC-AML中频率>70%。

临床怎么用

  • 对AML患者识别pDC扩增有助于识别RUNX1突变相关独特亚群并评估不良风险。
  • CD123靶向治疗(tagraxofusp)可能成为pDC-AML的潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Plasmacytoid dendritic cells (pDCs) are the principal natural type I interferon-producing dendritic cells. Neoplastic expansion of pDCs and pDC precursors leads to blastic plasmacytoid dendritic cell neoplasm (BPDCN), and clonal expansion of mature pDCs has been described in chronic myelomonocytic leukemia. The role of pDC expansion in acute myeloid leukemia (AML) is poorly studied. Here, we characterize patients with AML with pDC expansion (pDC-AML), which we observe in ∼5% of AML cases. pDC-AMLs often possess cross-lineage antigen expression and have adverse risk stratification with poor outcome. RUNX1 mutations are the most common somatic alterations in pDC-AML (>70%) and are much more common than in AML without pDC expansion and BPDCN. We demonstrate that pDCs are clonally related to, as well as originate from, leukemic blasts in pDC-AML. We further demonstrate that leukemic blasts from RUNX1-mutated AML upregulate a pDC transcriptional program, poising the cells toward pDC differentiation and expansion. Finally, tagraxofusp, a targeted therapy directed to CD123, reduces leukemic burden and eliminates pDCs in a patient-derived xenograft model. In conclusion, pDC-AML is characterized by a high frequency of RUNX1 mutations and increased expression of a pDC transcriptional program. CD123 targeting represents a potential treatment approach for pDC-AML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Xiao W, Chan A, Waarts MR, et al. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood. 2021. PMID: 32871587. doi:10.1182/blood.2020007897

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。